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Abstract
Background: The understanding of early events following TB exposure is limited by traditional tests that rely on
detection of an immune response to infection, which is delayed, or on imaging tests with low sensitivity for early
disease. We investigated for evidence of lung abnormalities in heavily exposed TB contacts using PET/MRI.
Methods: 30 household contacts of 20 index patients underwent clinical assessment, IGRA testing, chest x-ray and
PET/MRI scan using 18-F-FDG. MRI images were examined by a radiology/nuclear medicine dual-qualified physician
using a standardised report form, while PET/MRI images were examined independently by another radiology/
nuclear medicine dual-qualified physician using a similar form. Standardised uptake value (SUV) was quantified for
each abnormal lesion.
Results: IGRA was positive in 40%. PET/MRI scan was abnormal in 30%, predominantly FDG uptake in hilar or
mediastinal lymph nodes and lung apices. We did not identify any relationship between PET/MRI findings and
degree of exposure or IGRA status.
Conclusion: PET-based imaging may provide important insights into the natural history following exposure to TB
that may not be available from traditional tests of TB immune response or imaging. The clinical significance of the
abnormalities is uncertain and merits further investigation in longitudinal studies.
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Background
It is increasingly recognised that patients infected with
tuberculosis (TB) may have a spectrum of disease, from
incipient disease to subclinical disease activity and eventu-
ally clinically-manifest active disease [1, 2]. Studies of the
early manifestations of disease following TB exposure have
been limited by the tools available. Traditional approaches
for investigating patients for TB, which are limited to
symptom screening, a chest x-ray (CXR) plus either a Tu-
berculin Skin Test (TST) or Interferon Gamma Release
Assay (IGRA), provide poor discrimination of early events
after exposure. Studies using Computed Tomography
(CT) imaging have identified changes consistent with
active TB in just under a third of TST or IGRA positive
TB contacts [3–7].
PET-based imaging has shown particular promise for
identifying clinically-significant abnormalities in asymp-
tomatic patients with TB [8, 9]. In a study of HIV
infected patients with latent TB, PET/CT also identified
abnormalities consistent with subclinical TB in just
under a third of cases [8]. Another small PET/CT study
identified lymph node activity in four of five asymptom-
atic IGRA-positive TB contacts [9]. The aim of our study
was to investigate a much larger group of contacts using
PET magnetic resonance imaging (PET/MRI) to look for
early abnormalities.
Methods
The study recruited from July 2013 to April 2016. There
were 2 recruitment sites, National University Hospital
(NUH), and TB Control Unit (the national TB clinic
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which sees all the TB contacts in Singapore). At NUH,
household contacts were approached through index pul-
monary TB cases attending as inpatients. At TBCU,
household contacts attending for routine screening as
part of the national programme were approached about
the study. Participants were eligible for inclusion if they
were living in the same house as an index case (defined
as an individual with smear positive pulmonary TB) for
at least one month. Exclusion criteria were treatment for
TB in the last year (treatment for LTBI was allowed),
presence of metallic implants (contraindication for MRI)
and poorly controlled diabetes mellitus (interference
with uptake of the 18F-Fludeoxyglucose (FDG) used for
PET scan).
Participants were asked about exposure-related factors:
how long they had lived with the index patient; where
they slept relative to the index patient; and how fre-
quently they shared meals with them [10]. Participants
were asked about any clinical symptoms suggestive of
TB, smoking history and a physical examination was
performed. Data relating to the index case (de-identified)
was extracted from the national TB database (duration
of cough, date of presentation, sputum smear grade, TB
drug sensitivity and presence of cavitation on CXR. The
time between exposure and imaging was estimated from
the difference between the date the index patient first re-
ported symptoms or began to live in the same household
as the contact, whichever was later, and date of the of
the PET/MRI scan.
The National Healthcare Group Domain Specific Re-
view Board approved the study (2013/00116) including
waiver of consent to collect de-identified information
about the corresponding index patients from the national
TB database. All participants gave written informed
consent.
IGRA testing was performed using the QuantiFER-
ON®-TB Gold In-Tube Test (QIAGEN, Hilden, Germany).
A standard posteroanterior CXR was performed.
Where the routine hospital report identified abnormal-
ities of consolidation, abnormal lymph nodes, pleural
effusion or cavitation, x-rays were re-reviewed by a
second (independent) radiologist. Where the originally
reported findings were not confirmed on re-review, the
CXR was regarded as normal.
PET/MRI
PET/MRI was performed at the A*STAR-NUS Clinical
Imaging Research Centre (CIRC) in Singapore using a
Siemens Biograph mMR PET/MR scanner (Siemens
Healthcare, Erlangen, Germany). Participants received
an intravenous injection of 18F-FDG with a mean
activity of 148·6 ± 54·7MBq (mean ± s.d.). PET data was
acquired for 15 min at 60 min post-injection (62·3 ± 12.6
min [mean ± s.d.]). The PET images were reconstructed
using Ordinary-Poisson Ordered-Subset Expectation-
Maximisation (OP-OSEM) with three iterations and 21
subsets. A Gaussian post-smoothing filter of 6 mm full-
width at half maximum (FWHM) was applied. The
matrix size was 172 × 172, with a voxel size of 4·17 ×
4·17 mm and slice thickness of 2·03 mm.
The MRI data was acquired using 12-channel body
coils. Dixon images were collected for the purpose of
MR-based Attenuation Correction (MRAC). In addition,
all subjects underwent T2-weighted half-Fourier acquisi-
tion single-shot turbo spin-echo (HASTE) with Pro-
spective Acquisition CorrEction (PACE) and Diffusion
Weighted Imaging (DWI).
Image analysis
PET/MRI scans were read by two independent board
certified dual trained radiology/nuclear medicine physi-
cians (L.K.K. and J.H.) who did not have access to IGRA
or other results. J.H. analysed only the MRI images,
without having access to the PET images, while L.K.K
independently analysed the combined PET/MRI images.
Each reader recorded their findings on a standard data
collection form that included the presence and location
of consolidation, cavitation, pleural effusion, lymphaden-
opathy and nodules. For the purposes of the analysis of
the MRI images alone, a lymph node of > 1 cm in short
axis was considered enlarged and a nodule > 6 mm was
considered significant. For the purposes of PET/MRI
combined image analysis any lesion with standardized
uptake value (SUV) > 0.95 was considered abnormal
(based on a previous study using PET/CT that found
that a cut-off value of 1.05 had 100% sensitivity and spe-
cificity for distinguishing active from inactive tubercu-
loma [11], and a study that showed SUV values using
PET/MR are approximately 10% lower than PET/CT
[12]). For each lesion the maximum SUV (SUVmax) was
calculated.
The sample size of 30 was chosen based on pragmatic
considerations of feasibility (recruitment and work of
scans and analysis) and available funding, and was con-
sidered adequate to fulfil the descriptive objectives of
the study. Statistical analysis was performed using SPSS
version 21.
Results
34 contacts were screened for the study and 30 were
scanned (1 was excluded due to pregnancy and 3 with-
drew consent before scanning). The median age was 42
(range 22 to 66) years; 43% were male; and the ethnic
distribution was 47% Chinese, 33% Malay, 10% Indones-
ian, 7% Burmese and 3% Indian. Three contacts reported
comorbidities (asthma, 1, gastritis, 1 and hypertension
and hyperlipidaemia, 1). No contact reported a history
Molton et al. BMC Infectious Diseases           (2019) 19:83 Page 2 of 7
of HIV or diabetes mellitus. Four were current smokers
and one was an ex-smoker.
All contacts had slept in the same house as the index
patient for a median of 20 years (range 2 months – 54
years). Of these, 13% slept in the same bed, 33% in sep-
arate beds in the same room and 53% in separate rooms;
60% ate together daily, 23% less than daily, and 17%
never ate together.
The 20 index cases to which the contacts were linked
were all sputum smear positive, of which 40% were
grade ≥ 3+; all were culture positive; one had isoniazid
resistance and the others had fully susceptible TB; 40%
had cavitation on CXR.
Contacts were studied a median of 97 days (range 22–
752 days) after estimated first TB exposure. Six contacts
reported cough (duration one day to one year; CXR nor-
mal in all), three of which were productive of sputum
(cultures negative for TB). No contacts had fever, night
sweats, weight loss or haemoptysis.
The IGRA was positive in 12 (40%) contacts, negative
in 15 (one of whom converted to positive on routine
testing done 43 days later), indeterminate in one (tested
negative on repeat testing 57 days later) and not analysed
in two.
Four (13%) of the contacts had received isoniazid
treatment for latent TB prior to imaging (median of 17
days, range 7–44 days). The CXR was abnormal in one
contact (3%), showing minimal bilateral upper lobe
scarring.
Analysis of the MRI images alone revealed only a 15
mm right upper lobe pulmonary nodule in one contact
(Fig. 1 b (iii)) which was found to correspond to a
PET-avid pulmonary nodule (SUVmax 3.9) at the same
location on the independent analysis of the PET/MRI
combined images. Two further contacts with normal
PET/MRI scans (both never smokers) had nodules ≤6
mm detected on the review of the MRI alone, which
were not considered significant.
The analysis of the combined PET/MRI images re-
vealed abnormal metabolic activity in 9 (30%) partici-
pants (Fig. 1 a-f and Table 1). PET uptake was abnormal
in all 9 (uptake in mediastinal lymph nodes, 3; hilar
lymph nodes, 5; pulmonary nodule, 1; and other paren-
chymal lung uptake, 3). The SUVmax for these lesions
varied from 1.3 to 3·9. Subtle MRI lesions were identified
underlying the regions of FDG uptake in 2 out of the 3
contacts with parenchymal lung uptake (Fig. 1 f and g).
In the other contact with parenchymal uptake, diffuse
FDG uptake was seen in the anterior segment of the left
upper lobe (SUVmax 2.2) but no underlying lung
changes could be appreciated on MRI (Fig. 1 d).
The one contact with the abnormal CXR was found to
have bilateral pleural thickening and left apical scarring
on MRI review, and an SUVmax of 1.9 on PET/MRI
review. However this contact had a history of previously
-treated TB which could explain these findings and this
was not therefore considered an abnormality related to
the recent TB exposure.
Of the 9 contacts who had abnormal PET/MRI scans,
two had cough and four (44.4%) were IGRA positive.
The 9 contacts with abnormal scans were linked to 8
index patients (median cough duration of 5 weeks (range
1–104 weeks); smear grade ≥ 3+ in four; cavitary disease
in four). Two of the 9 contacts were on isoniazid treat-
ment for latent TB at the time of the scan (for 13 and
44 days).
Of the 27 contacts with available data on index patient
cough duration, 17 had exposure ≥90 days, 10 had ex-
posure < 90 days. Scans were abnormal in 2/10 (20%) of
those with short exposure and 6/17 (35%) of those with
long exposure. The prevalence of scan abnormalities was
31% in the IGRA positive group and 33% in the IGRA
negative group. There was no statistical association
found between abnormal PET/MRI scan and history of
cough (p = 1.00, 2-sided Fishers exact), intensity of ex-
posure to index case (proximity of sleeping, (p = 0.405,
2-sided Fishers exact); frequency of eating together, (p =
0.253, 2-sided Fishers exact)), estimated duration of ex-
posure, (p = 0.775, 2-tailed Mann-Whitney U), or smear
status of index case (p = 0.110, 2-sided Fishers exact).
There was no significant correlation between PET/MRI
SUVmax values and initial quantitative IGRA values
(Spearman r = 0.009; p = 0.979).
Across the whole cohort 11 contacts were ultimately
treated for latent TB. A check of the national dispensing
records revealed that no participants received treatment
for active TB over a median of 2.2 years of follow up
from date of scanning (range 1.2–3.9).
Discussion
Using the new approach of PET/MRI, we identified in-
creased metabolic activity in lymph nodes or lung paren-
chyma in approximately one third of heavily-exposed
household TB contacts. Although there were few study
eligibility criteria, healthy contacts who are motivated to
enter a study and undergo a PET scan may differ from
the general population of household contacts and this,
together with the small sample size, means that the
prevalence estimate may not be generalizable to the
broader population of contacts. Nevertheless, the fre-
quency of metabolic abnormalities appears much higher
than the expected prevalence of active TB in this popula-
tion (in a meta-analysis of 108 studies from high-income
settings, the prevalence of active TB among contacts was
only 1.4% [13]).
We did not scan a control population without house-
hold exposure to TB for ethical reasons and for funding
and practical limitations. Most of the lesions had relatively
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low SUVmax values and interpretation of these depends
on the background rate of lesions with low-level uptake in
the normal population. A large study in Japan reported
findings from 155,456 healthy people scanned with PET/
CT [14]. Only 212 (0.14%) had some form of false positive
inflammatory change in lung, and no lymph node false
positives were reported. This supports our interpretation
that the reported abnormalities in our study lie outside ex-
pectations for a healthy control population. In contrast,
another study of 179 healthy controls scanned with PET/
CT identified visually increased FDG uptake in hilar nodes
in 28% of individuals [15]. However, none of these nodes
had an SUVmax over 3, and even using this high thresh-
old as the limit of the normal range would not negate our
findings (two patients had higher SUVmax values; and the
high threshold does not apply to parenchymal disease).
One contact was identified as having diffuse FDG
uptake within the lung parenchyma with no underlying
structural abnormality on MRI, the significance of which
is uncertain. This may be due to embolization of injected
FDG, although this has previously been reported to
produce a discreet focus of uptake rather than diffuse
uptake [16]. While we cannot rule out all alternative
explanations for the abnormal findings such as recent
viral infection, TB is by far the most likely explanation
given the circumstances (definite ongoing household
exposure to a known case of TB, and a high IGRA positive
rate (40%, compared to a rate of 12.7% in the local
population [17]). Our findings are also plausible be-
cause studies using CT have also identified abnormal-
ities in up to a third of TB contacts [3–7], and the
nature and distribution of FDG uptake on PET/MRI
is consistent with a study using PET/CT that reported
lymph node activity in four of five TB contacts [9]. We did
not find any statistical correlation between FDG
abnormalities and degree or timing of exposure, which is
surprising if the changes are due to TB exposure. This
may be due to the small sample size.
(See figure on previous page.)
Fig. 1 Abnormal imaging findings in TB contacts. a. Participant 2. 61y female, asymptomatic, (i) CXR: normal (ii) PET/MRI: FDG-avid right
mediastinal lymph node (SUVmax 3.2); b. Participant 3. 35y female, asymptomatic, (i) CXR: normal (ii) PET/MRI: Spherical FDG-avid lesion in the
apex of the right lung (SUVmax 3.9) (iii) Increased signal observed on MRI (HASTE); c. Participant 8. 54y male, asymptomatic, (i) CXR: normal (ii)
PET/MRI: FDG-avid right hilar lymph node (SUVmax 2.4) and mediastinal lymph node (SUVmax 2.5); d. Participant 9. [914] 46y male, asymptomatic,
(i) CXR: normal (ii) PET/MRI: Diffuse left upper lobe parenchymal uptake (SUVmax 2.2) (iii) No underlying MRI changes; e. Participant 12. 30y male,
1 week of mild non-productive cough, (i) CXR: normal (ii) PET/MRI: Right hilar lymph node (SUVmax 2.6); f. Participant 14. [922] 25y male,
asymptomatic, (i) CXR: normal (ii) PET/MRI: RUL parenchymal uptake (1.3) (iii) Small underlying lesion identified on MRI images; g. Participant 16.
[924] 22y male, 1 week of mild non-productive cough, (i) CXR: normal (ii) PET/MRI: Patchy right middle lobe parenchymal uptake (2.8), (iii) Bilateral
underlying patchy changes identified on MRI. The area of right middle lobe uptake overlies an area of MRI abnormality; h. Participant 18. 46y
female, asymptomatic, (i) CXR: normal (ii) PET/MRI: Right hilar lymph node (SUVmax 2.2); i. Participant 30. 66y male, asymptomatic, (i) CXR: normal,
(ii) PET/MRI: several FDG-avid hilar lymph nodes (SUVmax = 2.8). (Note that all PET images are SUV images scaled between 0 (white) and 3 (black))
Table 1 PET and MR findings in the 9 contacts with abnormal scans
Patient
ID
Smoking
history
Finding(s)
on CXR
Finding(s) on analysis
of MRI images alone
Findings on analysis of combined PET/MRI images
(SUVmax)
Highest
SUVmax
IGRA Quantitative
IGRA (IU/ml)
2 Never
smoked
Nil Nil 1 right hilar LN (3.2) 3.2 Positive 2.12
3 Never
smoked
Nil 15 mm RUL nodule 1 RUL nodule (3.9)
1 mediastinal LN (3.1)
3.9 Positive 1.82
8 Current
smoker
Nil Nil 4 bilateral mediastinal nodes (2.1–2.5)
2 bilateral hilar nodes (1.6–2.4)
2.5 Positive 7.36
9 Never
smoked
Nil Nil Diffuse LUL parenchymal uptake (2.2)
No underlying MRI changes
2.2 Negative 0.01
12 Never
smoked
Nil Nil 1 right hilar LN (2.6) 2.6 Positive 0.58
14 Never
smoked
Nil Nil RUL parenchymal uptake (1.3)
Small lesion identified on MRI images underlying the FDG
uptake
1.3 Negative 0.00
16 Ex-smoker Nil Nil Patchy RML parenchymal uptake (2.8)
Bilateral patchy changes identified on MRI. The area of RML
uptake overlies an area of MRI abnormality
2.8 Negative 0.01
18 Never
smoked
Nil Nil 1 right hilar LN (2.2) 2.2 Negative 0.00
30 Never
smoked
Nil Nil 2 bilateral mediastinal LN (2.2–2.3)
8 bilateral hilar LN (2.6–2.8)
2.8 Negative 0.00
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The aetiology of the abnormal lesions that we ob-
served is uncertain. They may represent an early stage of
TB infection with active but low-level mycobacterial rep-
lication, sometimes referred to as “incipient disease” [2].
Another possibility may be that the FDG lymph node
uptake represents transient immune activity following
mycobacterial antigen presentation, which might poten-
tially result in control or clearance of infection. The
modest FDG activity (SUVmax 2–4) compared to active
TB (typically 10–12) is consistent with either interpret-
ation [18]. It is unknown whether presence of such early
lesions might identify individuals at higher risk of subse-
quent progression to active disease. Asymptomatic HIV
co-infected patients with abnormalities on PET/CT sug-
gestive of subclinical TB had a higher risk of developing
subsequent active clinical disease [8]. However, the le-
sions in that study were mainly parenchymal lesions,
whereas we found mainly lymph node abnormalities. We
did not systematically follow up the contacts, although
offered a repeat scan in those with changes (three agreed
to have repeat scans after an interval of 6 months (range
182–193 days) but showed no evidence of progression).
We also searched the national treatment database for
longer term outcomes and found that none had relapsed.
However the median duration of follow up (2 years) was
relatively short and these findings might confer a higher
risk of relapse in the longer term. Although HIV was
not tested as part of the study, no contact had known
HIV and the background prevalence of HIV in the local
population is only 0.001% [19]. In a population with a
low overall risk of reactivation, and a small sample size,
the absence of any cases of observed progression does
not negate the possibility of increased risk of
re-activation in those with PET/MRI abnormalities (lar-
ger studies would be needed with more practical bio-
markers to determine this, see below).
The high prevalence of abnormalities we observed are
even more remarkable given that we did not limit re-
cruitment to contacts who were IGRA positive; we
recruited independent of IGRA status because we did
not want to assume a priori that PET/MRI would be
normal in those who did not mount an IGRA response
following TB exposure. Indeed there was no correlation
between IGRA and scan abnormalities. The IGRA test is
based on the T-cell response to infection and the ob-
served PET activity also most likely reflects the immune
response as uptake by metabolically-active bacilli is likely
small given the low bacillary burden in this early disease
stage. The lack of concordance between the two investi-
gations may simply be due to the small sample size, but
might also reflect the difference between the standar-
dised antigenic stimulation with IGRA [20], and the nat-
ural immune response which is likely to evolve between
exposure and scan. Although the scans were performed
promptly after the identification of a contact, the time
for the index case to present introduced an unavoidable
delay in time between first exposure and scan, during
which resolution may have occurred. MRI has higher
sensitivity than CT for detecting nodal involvement in
patients with active pulmonary TB [21]. Previous studies
investigating PET in TB have all used PET/CT. As
lymph nodes appear to be the commonest site of sub-
clinical pulmonary activity in TB contacts, PET/MRI
may possibly be a preferred imaging modality over PET/
CT in research studies in TB contacts. PET/MRI has the
additional advantage of lower radiation dose than PET/
CT, which may be important for research applications in
healthy contacts.
Conclusions
Given the cost, radiation dose and practical challenges
involved in implementing at scale in large numbers of
contacts, it is unlikely that PET-based imaging will find
a clinical role in the screening of TB contacts. However,
it may have considerable value in research studies for
defining underlying differences in disease status that are
missed by the traditional clinical screening methods.
The ability to characterise clinical status in more detail
may provide a foundation for future studies to identify a
simpler and cheaper biomarker that may reflect these
subclinical changes seen on PET/MRI. However prior to
this larger PET imaging studies would be necessary to
confirm if the population with subclinical FDG uptake
indeed represents a population at higher risk of future
reactivation. Such biomarkers could then be applied on
a much larger scale for testing TB contacts and follow-
ing outcomes, to determine whether these changes are
predictive of relapse.
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